NOTCH3基因突变与结直肠癌免疫检查点抑制剂治疗疗效的关联性
Association of NOTCH3 Mutation with the Prognosis of Colorectal Cancer Patients Treated with Immune Checkpoint Inhibitors
摘要: 目的：探讨NOTCH3基因突变与结直肠癌免疫检查点抑制剂治疗疗效的关联性。方法：采用倾向性评分匹配的方法纠正混杂因素的影响，分析NOTCH3基因突变与微卫星不稳定(MSI-H)/超突变状态及免疫检查点抑制剂治疗预后的关联性。结果：55份NOTCH3突变、105份NOTCH3野生型结直肠癌测序样本分析示NOTCH3突变与MSI-H/超突变状态密切关联(关联系数rn = 0.464，P < 0.001)。11例NOTCH3突变、33例NOTCH3野生型晚期结直肠癌患者免疫检查点抑制剂治疗生存分析显示突变患者与野生型患者平均生存期为35.55个月vs 17.03个月(HR = 0.12，95%置信区间0.02~0.88，Log-rank P值 = 0.011)。结论：NOTCH3突变型晚期结直肠癌患者免疫检查点抑制剂治疗后预后更好。
Abstract: Objective: To analyze the correlation between NOTCH3 mutation with the prognosis of colorectal cancer (CRC) patients treated with immune checkpoint inhibitors (ICIs). Methods: Propensity score matching (PSM) adjustment method was applied to reduce the influence of confounding variables to assess the association of NOTCH3 mutation with the status of MSI-H and TMB and evaluate the cor-relation of NOTCH3 mutation with the prognosis of CRC patients treated with ICIs. Results: A total of 55 NOTCH3-mutant and 105 NOTCH3-wildtype colorectal cancer tissues were obtained and demon-strated that NOTCH3 mutation was closely associated with MSI-H/hypermutated status and the as-sociation coefficient (rn) was 0.464 (P < 0.001). Besides, a dataset consisting of 11 NOTCH3-mutant and 33 NOTCH3-wildtype CRC patients treated with ICIs was collected and survival analysis indi-cated that the mean survival time of NOTCH3-mutant CRC patients versus that of NOTCH3-wildtype CRC patients was 35.55 vs. 17.03 months (hazard ratio 0.12; 95% CI, 0.02~0.88; Log-rank P = 0.011). Conclusions: NOTCH3-mutant CRC patients had a better prognosis after ICIs therapy.
文章引用：李晶, 朱静娟, 李田军, 周娜, 张晓春, 姜曼. NOTCH3基因突变与结直肠癌免疫检查点抑制剂治疗疗效的关联性[J]. 临床医学进展, 2022, 12(7): 6677-6685. https://doi.org/10.12677/ACM.2022.127963

参考文献

[1] Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249. [Google Scholar] [CrossRef] [PubMed]
[2] Jenkins, R., Barbie, D. and Flaherty, K. (2018) Mechanisms of Resistance to Immune Checkpoint Inhibitors. British Journal of Cancer, 118, 9-16. [Google Scholar] [CrossRef] [PubMed]
[3] Pardoll, D. (2012) The Blockade of Immune Checkpoints in Cancer Im-munotherapy. Nature Reviews Cancer, 12, 252-264. [Google Scholar] [CrossRef] [PubMed]
[4] Homet, M.B. and Ribas, A. (2015) Anti-Programmed Cell Death Protein-1/Ligand-1 Therapy in Different Cancers. British Journal of Cancer, 112, 1421-1427. [Google Scholar] [CrossRef] [PubMed]
[5] André, T., Shiu, K., Kim, T., et al. (2020) Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. The New England Journal of Medicine, 383, 2207-2218. [Google Scholar] [CrossRef] 
[6] Overman, M., Lonardi, S., Wong, K., et al. (2018) Durable Clinical Benefit with Nivolumab plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 36, 773-779. [Google Scholar] [CrossRef] 
[7] Colon Cancer, Version 1, 2021 Clinical Practice Guide-lines in Oncology (NCCN Guidelines).
https://www.nccn.org
[8] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)结直肠癌诊疗指南[M]. 北京: 人民卫生出版社, 2021: 71-76.
[9] Samstein, R., Lee, C., Shoushtari, A., et al. (2019) Tumor Mutational Load Predicts Survival after Immunotherapy across Multiple Cancer Types. Nature Genetics, 51, 202-206. [Google Scholar] [CrossRef] [PubMed]
[10] Pang, J., Gindin, T., Man-sukhani, M., et al. (2020) Microsatellite Instability Detection Using a Large Next-Generation Sequencing Cancer Panel across Diverse Tumour Types. Journal of Clinical Pathology, 73, 83-89. [Google Scholar] [CrossRef] [PubMed]
[11] Price, T.J., Thavaneswaran, S., Burge, M., et al. (2016) Update on Optimal Treatment for Metastatic Colorectal Cancer from the ACTG/AGITG Expert Meeting: ECCO 2015. Expert Review of Anticancer Therapy, 16, 557-571. [Google Scholar] [CrossRef] [PubMed]
[12] Chen, S., Watson, P. and Parmigiani, G. (2005) Accuracy of MSI Testing in Predicting Germline Mutations of MSH2 and MLH1: A Case Study in Bayesian Meta-Analysis of Di-agnostic Tests without a Gold Standard. Biostatistics (Oxford, England), 6, 450-464. [Google Scholar] [CrossRef] [PubMed]
[13] Cheng, D., Mitchell, T., Zehir, A., et al. (2015) Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. The Journal of Molecular Diagnos-tics: JMD, 17, 251-264. [Google Scholar] [CrossRef] [PubMed]
[14] Alanazi, I.O. and Khan, Z. (2018) Endocrine and Cell Surface Receptor Signaling in Breast Carcinogenesis. In: Bulut, N., Ed., Breast Cancer and Surgery, IntechOpen, London. [Google Scholar] [CrossRef] 
[15] Wang, X., Xi, X., Wu, J., et al. (2015) MicroRNA-206 Attenuates Tumor Proliferation and Migration Involving the Down-Regulation of NOTCH3 in Colorectal Cancer. Oncology Reports, 33, 1402-1410. [Google Scholar] [CrossRef] [PubMed]
[16] Zhang, X., Shi, H., Yao, J., et al. (2020) FAM225A Facilitates Colorec-tal Cancer Progression by Sponging miR-613 to Regulate NOTCH3. Cancer Medicine, 9, 4339-4349. [Google Scholar] [CrossRef] [PubMed]
[17] Varga, J., Nicolas, A., Petrocelli, V., et al. (2020) AKT-Dependent NOTCH3 Activation Drives Tumor Progression in a Model of Mesenchymal Colorectal Cancer. Journal of Experimental Medicine, 217, e20191515. [Google Scholar] [CrossRef] [PubMed]
[18] Vinson, K.E., George, D.C., Fender, A.W., et al. (2016) The Notch Pathway in Colorectal Cancer. International Journal of Cancer, 138, 1835-1842. [Google Scholar] [CrossRef] [PubMed]
[19] Lin, A., Zhang, H., Hu, X., et al. (2020) Age, Sex, and Specific Gene Muta-tions Affect the Effects of Immune Checkpoint Inhibitors in Colorectal Cancer. Pharmacological Research, 159, Article ID: 105028. [Google Scholar] [CrossRef] [PubMed]
[20] Yaeger, R., Chatila, W.K., Lipsyc, M.D., et al. (2018) Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer. Cancer Cell, 33, 125-136e3. [Google Scholar] [CrossRef] [PubMed]
[21] Previs, R., Coleman, R., Harris, A., et al. (2015) Molecular Path-ways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 21, 955-961. [Google Scholar] [CrossRef] 
[22] Ntziachristos, P., Lim, J., Sage, J., et al. (2014) From Fly Wings to Targeted Cancer Therapies: A Centennial for Notch Signaling. Cancer Cell, 25, 318-334. [Google Scholar] [CrossRef] [PubMed]
[23] Stremitzer, S., Zhang, W., Yang, D., et al. (2015) Variations in Genes Involved in Dormancy Associated with Outcome in Patients with Resected Colorectal Liver Metastases. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 26, 1728-1733. [Google Scholar] [CrossRef] [PubMed]
[24] Verdegaal, E., de Miranda, N., Visser, M., et al. (2016) Neoantigen Landscape Dynamics during Human Melanoma-T Cell Interactions. Nature, 536, 91-95. [Google Scholar] [CrossRef] [PubMed]
[25] Becht, E., de Reyniès, A., Giraldo, N., et al. (2016) Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 22, 4057-4066. [Google Scholar] [CrossRef] 

为你推荐